NexCAR19: India’s CAR-T Cell Therapy

Cancer, especially blood-related types like leukemia and lymphoma, is complex and expensive to treat. Worldwide, CAR-T (Chimeric Antigen Receptor T-cell) therapy is seen as a revolutionary personalized medicine for cancer treatment. Recently, India achieved a significant milestone by developing its first indigenous CAR-T therapy, “NexCAR19.”

Development

  • Indigenous Collaboration: NexCAR19 is India's first indigenous CAR-T cell therapy, developed jointly by IIT Bombay, Tata Memorial Centre, and ImmunoACT (an IIT Bombay incubated company).
  • Target: This therapy targets the CD19 protein found on blood cancer cells like B-cell leukemia and lymphoma.
  • Approval: In October 2023, the Central Drugs Standard Control Organization (CDSCO) approved its ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Science & Technology